Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Koutsonanos, Dimitrios G ^a   Vassilieva, Elena V ^a   Stavropoulou, Anastasia ^c   Zarnitsyn, Vladimir G ^b   Esser, E Stein ^a   Taherbhai, Misha T ^a   Prausnitz, Mark R ^b   Compans, Richard W ^a   Skountzou, Ioanna ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; CELLULAR IMMUNITY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; MOUSE; NEEDLE; SKIN;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEEDLES; SKIN;

EID: 84860209610     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00357     Document Type: Article

References (55)

1. Fiore, A. E. et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.MMWRRecomm Rep 57, 1-60 (2008).
2. Osterholm,M. T. Preparing for the next pandemic. N Engl J Med 352, 1839-1842 (2005).
3. Camilloni, B. et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 28, 7536-7541 (2010).
4. Iorio, A. M. et al. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home. Vaccine 24, 6615-6619 (2006). (Pubitemid 46107149)
5. Baldo, V. et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin DevImmunol 2010, 517198 (2010).
6. Bickel, M. et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 24, F31-35 (2010).
7. Cooper, C. et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PloS one 6, e17758 (2011).
8. Nolan, T. et al. Immunogenicity of amonovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA : the journal of the American Medical Association 303, 37-46 (2010).
9. Myers, E. R., Misurski, D. A. & Swamy, G. K. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am JObstet Gynecol 204, S128-140 (2011).
10. Blanchard-Rohner, G. & Siegrist, C. A. Vaccination during pregnancy to protect infants against influenza: why and why not? Vaccine 29, 7542-7550 (2011).
11. Clarke, C. E. & McComas, K. Seeking and Processing Influenza Vaccine Information: A Study of Health Care Workers at a Large Urban Hospital. Health Commun (2011).
12. Medina, R. A. & Garcia-Sastre, A. Influenza A viruses: new research developments. Nat Rev Microbiol 9, 590-603 (2011).
13. Guan, R. et al. Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus. Proceedings of the National Academy of Sciences of the United States of America 108, 13468-13473 (2011).
14. Sridharan, H., Zhao, C. & Krug, R. M. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. The Journal of biological chemistry 285, 7852-7856 (2010).
15. Nichol, K. L. & Treanor, J. J. Vaccines for seasonal and pandemic influenza. J Infect Dis 194 Suppl 2, S111-118 (2006). (Pubitemid 44630954)
16. Fiore, A. E. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices(ACIP), 2010. MMWR Recomm Rep 59, 1-62 (2010).
17. Beyer, W. E., Nauta, J. J., Palache, A. M., Giezeman, K. M. & Osterhaus, A. D. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 29, 5785-5792 (2011).
18. Koyama, S. et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2, 25ra24 (2010).
19. Gross, P. A. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J Infect Dis 136 Suppl, S616-625 (1977). (Pubitemid 8286936)
20. Gross, P. A. et al. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 136, 623-632 (1977). (Pubitemid 8223673)
21. Gross, P. A. & Ennis, F. A. Influenza vaccine: split-product versus whole-virus types-How do they differ. N Engl J Med 296, 567-568 (1977). (Pubitemid 8071482)
22. McElhaney, J. E. Influenza vaccine responses in older adults. Ageing Res Rev 10, 379-388 (2011).
23. Ellebedy, A. H. & Webby, R. J. Influenza vaccines. Vaccine 27 Suppl 4, D65-68 (2009).
24. Marcelin, G. et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 202, 1634-1638 (2010).
25. Koutsonanos, D. G. et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 204, 582-591 (2011).
26. Koutsonanos, D. G. et al. Transdermal influenza immunization with vaccinecoated microneedle arrays. PloS one 4, e4773 (2009).
27. Sullivan, S. P. et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 16, 915-920 (2010).
28. Zhu, Q. et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proceedings of the National Academy of Sciences of the United States of America 106, 7968-7973 (2009).
29. Sun, J., Madan, R., Karp, C. L. & Braciale, T. J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. NatMed 15, 277-284 (2009).
30. Slifka, M. K. Immunological memory to viral infection. Curr Opin Immunol 16, 443-450 (2004).
31. Maltezou, H. C. & Tsakris, A. Vaccination of health-care workers against influenza: our obligation to protect patients. Influenza and other respiratory viruses 5, 382-388 (2011).
32. Kenah, E., Chao, D. L., Matrajt, L., Halloran, M. E. & Longini, I. M., Jr. The global transmission and control of influenza. PloS one 6, e19515 (2011).
33. Rimmelzwaan, G. F., Bodewes, R. & Osterhaus, A. D. Vaccination strategies to protect children against seasonal and pandemic influenza. Vaccine 29, 7551-7553 (2011).
34. Nair, H. et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review andmeta-analysis. Lancet 378, 1917-1930 (2011).
35. Zambon,M. Assessment of the burden of influenza in children. Lancet 378, 1897-1898 (2011).
36. Palache, A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 29, 9459-9466 (2011).
37. Osterhaus, A., Fouchier, R. & Rimmelzwaan, G. Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci 366, 2766-2773 (2011).
38. WHO. Public Health Research Agenda for Influenza (World Health Organization, 2009).
39. Collin, N. & de Radigues, X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 27, 5184-5186 (2009).
40. Molinari, N. A. et al. The annual impact of seasonal influenza in the US:measuring disease burden and costs. Vaccine 25, 5086-5096 (2007).
41. CDC. Flu Vaccine Effectiveness: Questions and Answers for Health Professionals. (Centers for Disease Control and Prevention, Atlanta, GA, 2011).
42. Nelson, K. S., Janssen, J. M., Troy, S. B. & Maldonado, Y. Intradermal fractional dose inactivated polio vaccine: A review of the literature. Vaccine (2011).
43. Brown, D., Fooks, A. R. & Schweiger, M. Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels. Adv Prev Med 2011, 601789 (2011).
44. Kommareddy, S. et al. Dissolvable microneedle patches for the delivery of cellculture- derived influenza vaccine antigens. J Pharm Sci (2011).
45. Kenney, R. T., Frech, S. A., Muenz, L. R., Villar, C. P. & Glenn, G. M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351, 2295-2301 (2004). (Pubitemid 39552745)
46. Van Damme, P. et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27, 454-459 (2009).
47. Naito, S. et al. Antigen-loaded dissolving microneedle array as a novel tool for percutaneous vaccination. Vaccine (2011).
48. Simon, J. K. et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jetinjector. Vaccine 29, 9544-9550 (2011).
49. Kim, Y. C., Quan, F. S., Compans, R. W., Kang, S. M. & Prausnitz, M. R. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 11, 1193-1201 (2010).
50. Compans, R. W. Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J Virol 14, 1307-1309 (1974).
51. Skountzou, I., Quan, F. S., Jacob, J., Compans, R. W. & Kang, S. M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24, 6110-6119 (2006). (Pubitemid 44175614)
52. Reed, L. J.a.M., H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27, 493-497 (1938).
53. Skountzou, I. et al. Incorporation of glycosylphosphatidylinositol- anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. JVirol 81, 1083-1094 (2007). (Pubitemid 46167831)
54. WHO/CDS/CSR/NCS. WHO Manual of Animal Influenza Diagnosis and Surveillance. Department of Communicable Disease Surveillance and Response (2002).
55. Crotty, S., Aubert, R. D., Glidewell, J. & Ahmed, R. Tracking human antigenspecific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 286, 111-122 (2004). (Pubitemid 38490401)